Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 12/20 | 0.77 |
| ▸ | CHRNA10 | Q9GZZ6 | 12/20 | 0.77 |
| ▸ | CHRNA9 | Q9UGM1 | 12/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.55 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13267862 | 0.93 | CHRNA7 (0.88) | CHRNA7CHRNA10CHRNA9LMNACHRNB2 | |
| SCHEMBL12638115 | 0.87 | CHRNA7 (1.00) | CHRNA7CHRNA10CHRNA9LMNACHRNB2 | |
| SCHEMBL13262501 | 0.83 | CHRNA7 (0.88) | CHRNA7CHRNA10CHRNA9LMNACHRNB2 | |
| SCHEMBL4402115 | 0.81 | BCHE (0.50) | CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL4407138 | 0.79 | KDM4E (0.53) | CHRNA7CHRNA10CHRNA9LMNAHDAC1 | |
| SCHEMBL13231574 | 0.77 | CHRNA7 (1.00) | CHRNA7CHRNA10CHRNA9LMNACHRNB2 | |
| SCHEMBL4403897 | 0.77 | HDAC1 (0.48) | CHRNA7CHRNA10CHRNA9LMNAHDAC1 | |
| SCHEMBL28336420 | 0.76 | CHRNA7 (0.61) | CHRNA7CHRNA10CHRNA9LMNACHRNB2 | |
| SCHEMBL4406234 | 0.75 | CHRNA7 (0.77) | CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL4230954 | 0.75 | CHRNA7 (0.55) | CHRNA7CHRNA10CHRNA9LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178678-B2 | Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069432-A1 | Bis-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA5, CHRNA4 | CHRNA7 7/4885CHRNA10 4/4885CHRNA9 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.